An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone) in Children With Autism Spectrum Disorder
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
Price : $35 *
At a glance
- Drugs Vatiquinone (Primary)
- Indications Autistic disorder; Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors BioElectron Technology
- 31 Aug 2018 Biomarkers information updated
- 09 Mar 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 07 Oct 2014 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.